R. Biamonte

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno et al. · Journal of Clinical Oncology · 2004 · 164 citations · Full text

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Sandro Pignata, Sabino De Placido, R. Biamonte et al. · BMC Cancer · 2006 · 115 citations · Full text

Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients

Domenica Lorusso, Gabriella Ferrandina, Stefano Greggi et al. · Annals of Oncology · 2003 · 94 citations

Phase Iii Multicenter, Medicine, Metronomic Therapy +10

De Gramont Schedule is a Very Low Toxic and Effective Regimen in Low Performance Status Patients Affected by Metastatic Gastric Cancer: Preliminary Report

Antonio Rea, Gennaro Gadaleta‐Caldarola, Claudia Sandomenico et al. · Tumori Journal · 2002 · 68 citations

Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine

Salvatore Turano, Candida Mastroianni, Caterina Manfredi et al. · Journal of Neuro-Oncology · 2009 · 17 citations

Surgical Oncology, Medicine, Surgical Pathology +5